Ilya Rachman

Ilya M. Rachman, MD, PhD, is an American physician-scientist, biotechnology executive and cell biologist who is the founder, Chairman and Chief Executive Officer of Immix Biopharma, Inc. He has served as Chairman and CEO since the company’s founding in 2012 and has also served as Chief Scientific Officer since March 2026. At Immix Biopharma, Rachman oversees the company and its scientific mission, including its work in cell therapy and AL amyloidosis.

Early life and background

Ilya Rachman received his Bachelor’s degree from the University of Iowa. He is a United States citizen and is based in Los Angeles, California.

His interest in medicine and therapeutic development developed through his experience treating patients. After treating thousands of patients, Rachman became increasingly interested in developing new therapies so that patients facing limited treatment options could have additional possibilities. This experience contributed to his decision to pursue business training and later establish Immix Biopharma. His stated career influences include Dennis Slamon and Rochelle Cohen.

Education and medical training

Ilya Rachman attended high school in Iowa, United States. He received a Bachelor of Science degree from the University of Iowa and later earned a joint MD/PhD degree from the University of Illinois Chicago, where he conducted original research in neuroendocrinology. He subsequently received an Executive MBA from the University of California, Los Angeles (UCLA).

He also trained in medicine and medical research at UCLA Health. His academic and professional background combined clinical medicine, scientific research and business education, forming the basis for his later work in biotechnology and therapeutic development.

Medical and scientific career

Rachman began his professional career as a physician and later worked as a physician-scientist at Cedars-Sinai Medical Center and UCLA Health. His experience included clinical medicine, medical research, neuroendocrinology and experimental oncology.

Before founding Immix Biopharma, he established a clinical research organization that conducted clinical trials involving drugs developed by large pharmaceutical companies through Phase III and Phase IV clinical trials.

Rachman has also been described as a cell biologist and has a scientific publication record represented through a Google Scholar profile. He is named as an inventor on a number of patents associated with Immix Biopharma.

Founding of Immix Biopharma

Ilya founded Immix Biopharma, Inc. in 2012. His decision to create the company was influenced by his experience treating patients who had exhausted available therapeutic options and his interest in moving from clinical practice toward the development of new treatments.

Immix Biopharma was established with the objective of applying scientific and academic research to therapeutic development. Its initial work was associated with oncology, while the company later expanded its focus toward advanced cell therapies and other immune-based approaches.

Rachman has served as Chairman and Chief Executive Officer since the company’s inception and assumed the additional role of Chief Scientific Officer in March 2026. His responsibilities include oversight of the company as a whole and its scientific mission.

Immix Biopharma and AL amyloidosis

Under Rachman’s leadership, Immix Biopharma has focused on the development of therapies intended to harness the immune system through cell therapies and other modalities.

The company’s stated mission is to: harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures in autoimmune and other indications.

A principal therapeutic focus for Immix Biopharma is AL amyloidosis, a disease in which abnormal plasma cells produce toxic light chains that can accumulate in organs including the heart, kidneys and liver and may contribute to organ failure.

NXC-201

Immix Biopharma’s lead candidate is NXC-201, a sterically optimized BCMA-targeted chimeric antigen receptor T-cell therapy being developed for relapsed or refractory AL amyloidosis.

NXC-201 incorporates a proprietary CD3ζ signaling domain, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. The therapeutic approach is intended to enable the immune system to recognize and eliminate the source of toxic light chains associated with AL amyloidosis.

Rachman oversees Immix Biopharma’s scientific direction as the company advances its work in AL amyloidosis and cell therapy.

Leadership and business experience

Ilya Rachman has extensive experience working with investors, boards, partners and regulators through his leadership of Immix Biopharma. His role spans scientific strategy, corporate leadership and therapeutic development.

His professional background combines:

• Clinical medicine
• Physician-scientist experience
• Cell biology
• Neuroendocrinology research
• Experimental oncology
• Clinical-trial development
• Biotechnology company leadership
• Scientific strategy
• Public-company operations

His leadership approach is closely tied to Immix Biopharma’s long-term mission of developing immune-based therapies for serious diseases.

Research and publications

Ilya Rachman has conducted scientific research in neuroendocrinology and has experience in experimental oncology and clinical research. His professional materials identify a Google Scholar profile containing his scientific publications and research record.

He is also named as an inventor on a number of Immix Biopharma patents. The specific patent titles and numbers were not listed in the submitted biography documents.

External links

• Ilya Rachman on LinkedIn
• Ilya Rachman on X
• Ilya Rachman Google Scholar Profile
• Immix Biopharma on LinkedIn
• Nexcella on LinkedIn